Apigenin segmentation by type distinguishes three principal categories: natural extracts derived from botanical sources, synthetic apigenin produced through chemical synthesis, and semi‑synthetic variants obtained by modifying natural isolates. Natural extracts, which account for roughly 55 % of total volume, dominate the market due to consumer preference for minimally processed phytochemicals and the established supply chain from chamomile, parsley, and celery. Synthetic apigenin, representing about 30 % of the market, contributes higher purity levels and cost efficiencies for large‑scale pharmaceutical manufacturing, though regulatory scrutiny can limit its adoption in food‑grade applications. Semi‑synthetic apigenin, comprising the remaining 15 %, bridges the gap by enhancing bioavailability while retaining a natural provenance, making it attractive for nutraceutical formulations that require both efficacy and a “natural” label. Collectively, these type segments shape the overall market size by influencing pricing dynamics, regulatory pathways, and end‑user acceptance, and they form the foundation for the subsequent application‑level analysis. Therefore, strategic investment in extraction technology and synthetic route optimization remains pivotal for sustaining growth across all type segments.
